Studies CGRP-targeting migraine preventive medicines in real-world patients
Observes adults with migraine who take CGRP-targeting preventive drugs over 2 years.
Key facts
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Where
- Miami, United StatesSee the siteAlso in 12 other countries, 25 sites
- Trial code
- Registry title
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
- Status
- Recruiting
- People taking part
- 700 people, planned
- Started
- 2 Jan 2024
- Planned end
- Jan 2026
- Type of study
- Observational
- Treatments tested
- CGRP antibody or gepant
- Record updated
- 8 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who have been prescribed a CGRP-targeting preventive medicine and are followed over 2 years.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Migraine diagnosed according to ICHD-III.
- Earlier treatment
- Must have been prescribed erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant, following the prescriber's criteria and local reimbursement rules.
Main reasons for not taking part
- Headache other than migraine
- Active severe psychiatric condition that may affect the ability to consent
- Cognitive impairment that may affect the ability to consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Migraine diagnosis according to ICHD-III
- Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations
- Signature of informed consent
Who cannot take part
- Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study
- Presence of headache different from migraine
Where in United States
Also in 12 other countries, 25 sites
- University of Miami Miller School of MedicineMiami, United StatesContact: Teshamae S MonteithTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
The group in the trial
- Migraine Patients
Migraine patients who initiate a CGRP-targeted treatment
Treatment: CGRP antibody or gepant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
- Plain-language title
- Studies CGRP-targeting migraine preventive medicines in real-world patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 September 2025